Tipranavir (formerly known as PNU-140690) is the first of a new class of nonpeptide protease inhibitors, the dihydropyrone sulfonamides. Tipranavir was developed and is marketed by Boehringer Ingelheim with the trade name Aptivus. It was synthesized from coumarin and sulfonamide compounds as well as others. The chemical structure is shown in Figure 247.1.
Tipranavir / S. Rusconi - In: Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition / [a cura di] L. M Grayson, S. Cosgrove, S. Crowe, W. Hope, J. MCCarthy, J. M Mills. - Riedizione. - [s.l] : CRC Press : American Society for Microbiology, 2017 Nov. - ISBN 9781498747950. - pp. 4158-4179 [10.1201/9781315152110]
Tipranavir
S. Rusconi
Primo
2017
Abstract
Tipranavir (formerly known as PNU-140690) is the first of a new class of nonpeptide protease inhibitors, the dihydropyrone sulfonamides. Tipranavir was developed and is marketed by Boehringer Ingelheim with the trade name Aptivus. It was synthesized from coumarin and sulfonamide compounds as well as others. The chemical structure is shown in Figure 247.1.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Rusconi Stefano_Tipranavir Kucers' The Use of Antibiotics_Volume III (2 MB).pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
2.54 MB
Formato
Adobe PDF
|
2.54 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
